GoodRx Holdings, Inc. (GDRX)
| Market Cap | 1.11B-26.0% |
| Revenue (ttm) | 785.23M |
| Net Income | 16.25M |
| EPS | 0.05 |
| Shares Out | 107.18M |
| PE Ratio | 65.00 |
| Forward PE | 9.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 548,455 |
| Open | 3.24 |
| Previous Close | 3.27 |
| Day's Range | 3.23 - 3.30 |
| 52-Week Range | 1.77 - 5.81 |
| Beta | 1.69 |
| Analysts | Hold |
| Price Target | 3.95(+21.54%) |
| Earnings Date | Nov 3, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About GDRX
GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscription programs and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. In addition, the company provides healthcare products and solutions for dogs, cats, and other pets. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$GDRX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in GDRX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by GDRX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
GDRX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
GDRX Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Prescription transactions revenue | $106.39M | 53.09% |
| Pharma Direct revenue | $61.63M | 30.75% |
| Subscription revenue | $28.51M | 14.23% |
| Other revenue | $3.88M | 1.94% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New GDRX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to GDRX from public contracts
Source: USAspending.gov
GDRX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from GDRX’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score